Literature DB >> 23731603

[Analgesic efficacy of topical lidocaine for vaso-occlusive crisis in children with sickle cell disease].

J Rasolofo1, M Poncelet, V Rousseau, P Marec-Berard.   

Abstract

Pain associated with vaso-occlusive crisis is the main cause of hospitalization in children with sickle cell disease. Recent studies have suggested that pain might have a neuropathic component. Lidocaine patches are commonly prescribed as a topical analgesic in adult neuropathic pain. This study reports the efficacy and safety of such treatment in 6 patients with sickle cell disease, aged 6-18 years, who had been hospitalized for vaso-occlusive crisis after failure of the standard analgesic treatment. These data have led to setting up a confirmatory phase II trial, which is currently underway.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23731603     DOI: 10.1016/j.arcped.2013.04.013

Source DB:  PubMed          Journal:  Arch Pediatr        ISSN: 0929-693X            Impact factor:   1.180


  5 in total

1.  Lidocaine 5%-medicated plaster (Versatis) for localised neuropathic pain: results of a multicentre evaluation of use in children and adolescents.

Authors:  John M Goddard; Rebecca L Reaney
Journal:  Br J Pain       Date:  2018-01-31

2.  The Use of Cannabis by Patients with Sickle Cell Disease Increased the Frequency of Hospitalization due to Vaso-Occlusive Crises.

Authors:  Samir K Ballas
Journal:  Cannabis Cannabinoid Res       Date:  2017-07-01

Review 3.  Localized neuropathic pain: an expert consensus on local treatments.

Authors:  Gisèle Pickering; Elodie Martin; Florence Tiberghien; Claire Delorme; Gérard Mick
Journal:  Drug Des Devel Ther       Date:  2017-09-13       Impact factor: 4.162

Review 4.  Topical Lidocaine for Chronic Pain Treatment.

Authors:  Marion Voute; Véronique Morel; Gisèle Pickering
Journal:  Drug Des Devel Ther       Date:  2021-09-29       Impact factor: 4.162

Review 5.  The role of the arginine metabolome in pain: implications for sickle cell disease.

Authors:  Nitya Bakshi; Claudia R Morris
Journal:  J Pain Res       Date:  2016-03-30       Impact factor: 3.133

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.